Here’s what you should know.
1. Boston Scientific revised its year forecast to between $1.09 and $1.11 per share on a revenue of $8.34 billion to $8.39 billion. It previously was at $1.07 to $1.11 per share on a revenue of $8.27 billion to $8.37 billion.
2. Its also adjusted its fourth quarter earnings to between $0.27 to $0.29 per share on a revenue of $2.14 billion to $2.19 billion. Analysts pegged its Q4 ratings at $0.29 per share on $2.15 billion in revenue.
3. Boston Scientific’s MedSurg saw a 15 percent increase in sales during Q3 to $753 million.
4. Boston Scientific expects to complete its acquisition of EndoChoice by the end of the fourth quarter.
5. The company reported a profit of $228 million during Q3. Last year it reported a loss of $198 million.
6. Cardiovascular products remain its market leader. Sales grew 13 percent to $825 million in Q3.
More articles on gastroenterology/endoscopy:
Embarrassment may be to blame for underdiagnosis of GI conditions: 5 study insights
Boston Scientific unveils Resolution 360 Clip; Fujifilm launches next generation endoscopy system & more: 3 GI company key notes
GI leader to know: Dr. Thomas E. Trouillot of Colorado Gastroenterology
